← Back
Data updated: Mar 29, 2026
SMITH AND NEPHEW
CardiovascularOncologyGastroenterology
Biotech
SMITH AND NEPHEW is a biotechnology company focused on Cardiovascular, Oncology, Gastroenterology.
1965
Since
22
Drugs
-
Trials
142
Approved (2yr)
Key Drugs
No active drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
HEPARIN SODIUM 2026-02-20
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
FLUOROURACIL 2026-02-10
Labeling
FLUOROURACIL 2026-02-10
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 50%
3 drugs
Oncology 17%
1 drugs
Gastroenterology 17%
1 drugs
Neurology 17%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Active (7)
Discontinued (15)
HEPARIN SODIUM FUROSEMIDE HALOPERIDOL HYDROXYZINE HYDROCHLORIDE TRIMETHOBENZAMIDE HYDROCHLORIDE METOCLOPRAMIDE HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE PROCHLORPERAZINE EDISYLATE PROCAINAMIDE HYDROCHLORIDE DOPAMINE HYDROCHLORIDE HEPARIN LOCK FLUSH PHENYTOIN SODIUM AMINOPHYLLINE DROPERIDOL METHYLDOPATE HYDROCHLORIDE
Company Info
- First Approval
- 1965-06-04
- Latest
- 2019-08-26
- Applications
- 44